COMMUNIQUÉS West-GlobeNewswire

Byondis to Profile Potential of Platform Technologies at World ADC San Diego, Advancing Strategy to Lead the Antibody-Drug Conjugate Field
07/10/2026
Lead ADC candidate BYON14156 harnesses company’s first-in-class antifolate payload platform to overcome major payload resistance challenge seen in current and next-generation ADCs Advancement of IND-enabling package [...]
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
07/10/2026
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” [...]
Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development
07/10/2026
- Three-phase, 36-month award aims to extend BrainEx perfusion from 24 hours to up to two weeks, enabling longitudinal studies of human brain biology and therapeutic responses - NEW HAVEN, Conn., Oct. 07, 2026 (GLOBE [...]
AltruBio to Present Data from ALTB-268 Phase 2a Trial on Ulcerative Colitis at United European Gastroenterology (UEG) Week 2026
07/10/2026
SAN FRANCISCO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and [...]
Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
07/10/2026
ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has defined as supportive of potential approval Atsena also reported new data [...]
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
07/10/2026
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative [...]
Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
07/10/2026
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia [...]
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
07/10/2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that [...]
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
07/10/2026
Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira [...]
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
07/10/2026
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no [...]
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
07/10/2026
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech [...]
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
07/10/2026
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS Phase [...]
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
07/10/2026
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in [...]
Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference
07/10/2026
Updated preclinical data and clinical trial-in-progress poster from the Harmony-HHT Phase 1/2 trial support the ongoing development of ATV-1601, an investigational oral allosteric inhibitor that selectively targets AKT1 [...]
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
07/10/2026
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
07/10/2026
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE [...]
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
07/10/2026
Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005 Cadrenal has received strong interest from potential strategic partners Cadrenal will [...]
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases
07/10/2026
Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATERTOWN [...]
SparkLabs Taiwan Announces Professor Shan-Qun Huang’s Planned Return to Taiwan to Support International Capital Cooperation and Financial Talent Development
07/10/2026
TAIPEI, Taiwan, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Following the completion of a recent phase of overseas investment research projects, Professor Shan-Chun Huang is planning to gradually shift the focus of his next stage [...]

Pages